OR WAIT null SECS
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP:-BC, interview Dr Robert Busch, to explore the advantages of SGLT2 inhibitors in chronic kidney disease, cardiovascular health, and their potential to improve overall patient outcomes.
To watch the video series component of this episode, click here.
1:21 Treatment landscape for CKD
3:42 Prevalence of CKD in people with diabetes
5:25 Mechanism of SGLT2 inhibitors
8:05 Benefits of SGLT2 inhibitors in non-diabetic patients
9:02 Cardiovascular benefits of SGLT2 inhibitors
11:24 Comparative efficacy of SGLT1,2 inhibitors
13:54 Impact of SGLT2 inhibitors on diabetes
16:50 Adverse effects of SGLT2 inhibitors
20:30 Effect of SGLT2 inhibitors in euglycemic DKA
23:08 Combining SGLT2 inhibitors with other diabetes medications
28:14 Combining finerenone with SGLT2 inhibitors